Signal Advisors Wealth LLC Purchases 420 Shares of Johnson & Johnson (NYSE:JNJ)

Signal Advisors Wealth LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% in the fourth quarter, Holdings Channel reports. The firm owned 7,969 shares of the company’s stock after purchasing an additional 420 shares during the period. Signal Advisors Wealth LLC’s holdings in Johnson & Johnson were worth $1,152,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. One Capital Management LLC boosted its position in shares of Johnson & Johnson by 22.2% during the 2nd quarter. One Capital Management LLC now owns 66,330 shares of the company’s stock valued at $9,695,000 after acquiring an additional 12,034 shares during the last quarter. Citizens Financial Group Inc. RI lifted its position in Johnson & Johnson by 82.8% during the second quarter. Citizens Financial Group Inc. RI now owns 180,501 shares of the company’s stock valued at $26,382,000 after purchasing an additional 81,780 shares during the last quarter. Wulff Hansen & CO. grew its stake in Johnson & Johnson by 14,424.6% in the 2nd quarter. Wulff Hansen & CO. now owns 1,625,299 shares of the company’s stock worth $237,554,000 after buying an additional 1,614,109 shares in the last quarter. Luts & Greenleigh Group Inc. bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $1,131,000. Finally, Excalibur Management Corp raised its position in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Excalibur Management Corp now owns 40,514 shares of the company’s stock valued at $5,921,000 after buying an additional 629 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $144.68 on Wednesday. The stock’s 50-day moving average is $149.12 and its 200 day moving average is $156.09. The company has a market cap of $348.33 billion, a PE ratio of 20.94, a P/E/G ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.66 earnings per share. Sell-side analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.43%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.